Basic Information
LSK BioPharma is a pharmaceutical company that specializes in the clinical development of promising therapies to address unmet medical needs in cancer. LSKB is developing two proprietary drug candidates: rivoceranib—a VEGFR-2 inhibitor that has demonstrated clinical efficacy in various solid tumors, and a BTK/JAK3 inhibitor with potential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressant.